Photo Credit: Douglas Cliff

Differences in the endpoints of HF-related symptoms, physical limitations, and body weight shown in trial for semaglutide for patients with HFpEF and T2D.

Significant differences in the endpoints of heart failure (HF)-related symptoms, physical limitations, and body weight marked a positive trial for semaglutide in HF with preserved ejection fraction (HFpEF) and T2D. After one year, the estimated treatment differences in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) and body weight were at 7.3 points and -6.4%.

The phase 3 STEP-HFpEF DM study (NCT04916470) randomized 617 adult patients with HFpEF and type-2 diabetes to receive either weekly semaglutide 2.4 mg after an escalation period of 16 weeks or matching placebo up to week 52.¹ The dual primary endpoints, presented by Mikhail Kosiborod, MD, assessed change in body weight and modification in HF-related symptoms measured by KCCQ-CSS.

Baseline findings showed a study cohort with 44% women, median age of 69 years, BMI of 37 kg/m², N-terminal pro-B-type natriuretic peptide level (NT-proBNP) of 493 pg/mL, and KCCQ-CSS of 59 points. One-third of the participants were already treated with SGLT2 inhibitors.

At 1 year, participants in the semaglutide group achieved a significantly greater 13.7-point change in KCCQ-CSS compared with 6.4 points in the placebo arm (P<0.001). Weight loss on the study drug at week 52 was determined at -9.8%, compared with -3.4% on placebo. This difference of -6.4% was also significant: P<0.001. At week 52, results also favored semaglutide for change in 6-minute walk distance, C-reactive protein, NT-proBNP, and HF-events compared with placebo.

Safety results observed serious adverse events in 17.7% of participants on semaglutide and 28.8% on placebo (P=0.002), fewer cardiac disorders in the semaglutide group (6.1% vs 13.1%), together with no signs for increased hypoglycemia or retinal disorders.

“Collectively, the results both from STEP-HFpEF and the STEP-HFpEF type-2 diabetes trials indicate that treatment with semaglutide is a valuable treatment approach in the management of patients with obesity-related HFpEF both with and without type-2 diabetes,” Dr. Kosiborod concluded.

Medical writing support was provided by Karin Drooff, MPH.
Copyright ©2024 Medicom Medical Publishers